Due to the compounds plasma half-life of approximately 3.86.9 hours [4] , twice-daily (BID) dosing may provide more sustained NNMT inhibition
Its also essential to note that while a B12 deficiency may contribute to cognitive decline, it is not the sole cause of dementia, Dr
AOD-9604 FDA Approval History At a glance FDA approval status / Never approved for any indication in the United States NDA filing history / No New Drug Application has ever been submitted to FDA Chemical identity / Synthetic peptide corresponding to amino acids 176-191 of human growth hormone, with a tyrosine residue added at the C-terminus Developer / Metabolic Pharmaceuticals Ltd (Melbourne, Australia), now defunct Clinical trial outcome / Phase IIb trial (2007) failed to meet primary efficacy endpoint for obesity FDA compounding status / Placed on Category 2 list
Key Features 50mg per capsule dosage 60 capsules per bottle Supports metabolic rate Helps fat oxidation pathways Oral capsule convenience Consistent daily dosing Why Choose 5 Amino-1MQ
Preliminary research suggests NMN supports synthesis of NAD+ in tissues, supporting cellular function and longevity, energy metabolism, aerobic capacity and glucose homeostasis